Gregory Glenn
Geen lopende functies
Vermogen: 87 660 $ op 31-03-2024
Profiel
Gregory M. Glenn richtte Intercell USA, Inc. op. Dr. Glenn is President-Research & Development bij Novavax, Inc. Daarvoor was hij Chief Scientific Officer bij Intercell AG, Chief Scientific Officer & Senior Vice President bij Intercell USA, Inc., Research Scientist bij Walter Reed Army Institute of Research en Associate-International Health bij Johns Hopkins Bloomberg School of Public Health. Dr. Glenn behaalde zijn doctoraal aan het Whitman College en zijn doctoraal aan de Oral Roberts University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
NOVAVAX, INC.
0.01% | 18-04-2023 | 18 339 ( 0.01% ) | 87 660 $ | 31-03-2024 |
Eerdere bekende functies van Gregory Glenn
| Bedrijven | Functie | Einde |
|---|---|---|
| NOVAVAX, INC. | Chief Tech/Sci/R&D Officer | 31-03-2023 |
Intercell AG
 Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Chief Tech/Sci/R&D Officer | 01-01-2010 |
| IOMAI CORPORATION | Founder | 01-01-2008 |
| Walter Reed Army Institute of Research | Corporate Officer/Principal | - |
| Johns Hopkins Bloomberg School of Public Health | Corporate Officer/Principal | - |
Opleiding van Gregory Glenn
| Oral Roberts University | Doctorate Degree |
| Whitman College | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| NOVAVAX, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Health Technology |
Intercell USA, Inc.
 Intercell USA, Inc. BiotechnologyHealth Technology Intercell USA, Inc. discovers and develops vaccines and immune system stimulants. The vaccine patch enhances the efficacy of existing vaccines, enables new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was founded by Gregory M. Glenn and Dean P. Lewis in September 1997 and is headquartered in Gaithersburg, MD. | Health Technology |
| Walter Reed Army Institute of Research |
